Serotonin warning for users of SSRIs

Share this article:
The FDA says development of a potentially life-threatening serotonin syndrome may occur in treatment with four selective serotonin reuptake inhibitors: Lilly's Cymbalta (duloxetine HCl) delayed release capsules, Wyeth's Effexor (venlafaxine HCL) tablets and Effexor extended release capsules, Lilly's Prozac (fluoxetine capsules and oral solution) and Lilly's Symbyax (olanzapine and fluoxetine HCL capsules).

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.